Neuralink, Elon Musk’s brain implant company, is expanding its global footprint. They plan to launch a clinical study in the United Kingdom. The study will test how its brain chips can enable patients with severe paralysis to control digital and physical devices using only their thoughts.

The company has partnered with University College London Hospitals Trust and Newcastle Hospitals to conduct the study. It will focus on patients living with paralysis caused by spinal cord injuries or Amyotrophic Lateral Sclerosis (ALS). This will offer them a chance to participate in cutting-edge neurotechnology research.

This move follows Neuralink’s recent $650 million funding round. It builds on the human trials, which began in 2024 after overcoming safety concerns. These concerns were initially raised by the US FDA, which had rejected its application in 2022.

Currently, five patients with severe paralysis are already using Neuralink’s brain implant. They interact with digital tools and physical devices through thought alone, showcasing the transformative potential of its technology.

Founded in 2016, Neuralink has raised about $1.3 billion to date. It is valued at roughly $9 billion, according to media reports citing PitchBook. This underscores growing investor confidence in the company’s ambitious vision for brain-computer interfaces.

Stocks Insights? Let the Analyst Guide You.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!